RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals ...

Fennec Pharma’s partner Norgine Pharma launches Pedmarqsi in Germany: Monday, February 10, 2025, 14:00 Hrs [IST] Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...

In March 2024, Fennec entered into an exclusive licensing ... PEDMARK is also recommended for the Adolescent and Young Adult (AYA) population by the National Comprehensive Cancer Network® as ...

Rosty Raykov, a director at Fennec Pharmaceuticals Inc. (NASDAQ:FENC), a company currently valued at $187 million, has sold 10,000 common shares of the company, according to a recent SEC filing.

THE WEEK’S MOST POPULAR SONGS RANKED BY ADULT R&B RADIO AIRPLAY DETECTIONS, AS MEAURED BY MEDIABASE AND PROVIDED BY LUMINATE. STATIONS ARE ELECTRONICALLY MONITORED 24 HOURS A DAY, 7 DAYS A WEEK.

RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today ...

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of ...